Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, Clarke P, Dalbeth N, Day RO, de Zoysa JR, Douglas B, Faull R, Harris DC, Hawley CM, Jones GRD, Kanellis J, Palmer SC, Perkovic V, Rangan GK, Reidlinger D, Robison L, Walker RJ, Walters G, Johnson DW; CKD-FIX Study Investigators. Badve SV, et al. Among authors: palmer sc. N Engl J Med. 2020 Jun 25;382(26):2504-2513. doi: 10.1056/NEJMoa1915833. N Engl J Med. 2020. PMID: 32579811 Clinical Trial.
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF. Palmer SC, et al. Ann Intern Med. 2010 Jul 6;153(1):23-33. doi: 10.7326/0003-4819-153-1-201007060-00252. Epub 2010 Jun 24. Ann Intern Med. 2010. PMID: 20439566 Free article. Review.
How to design a randomized controlled trial.
Navaneethan SD, Palmer SC, Smith A, Johnson DW, Strippoli GF. Navaneethan SD, et al. Among authors: palmer sc. Nephrology (Carlton). 2010 Dec;15(8):732-9. doi: 10.1111/j.1440-1797.2010.01428.x. Nephrology (Carlton). 2010. PMID: 21091924
Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis.
Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Copetti M, Graziano G, Tognoni G, Jardine M, Webster A, Nicolucci A, Zoungas S, Strippoli GF. Palmer SC, et al. Ann Intern Med. 2012 Mar 20;156(6):445-59. doi: 10.7326/0003-4819-156-6-201203200-00007. Ann Intern Med. 2012. PMID: 22431677 Free article. Review.
High-flux versus low-flux membranes for end-stage kidney disease.
Palmer SC, Rabindranath KS, Craig JC, Roderick PJ, Locatelli F, Strippoli GF. Palmer SC, et al. Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD005016. doi: 10.1002/14651858.CD005016.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972082 Free PMC article. Review.
Antiplatelet agents for chronic kidney disease.
Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Jardine MJ, Webster AC, Zoungas S, Strippoli GF. Palmer SC, et al. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008834. doi: 10.1002/14651858.CD008834.pub2. Cochrane Database Syst Rev. 2013. PMID: 23450589 Review.
287 results